The Forecast Is Bright: Recent Advances in Melanoma Treatment / Perspectives prometteuses: Récentes percées dans le traitement des mélanomes

Abstract

Get full access to this article

View all access options for this article.

References

American Cancer Society. Cancer facts & figures 2014. http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2014/index. Accessed June 21, 2015.

Davies

Ignell

Cox

. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-954.

Sullivan

LoRusso

Boerner

. Achievements and challenges of molecular targeted therapy in melanoma. Am Soc Clin Oncol Educ Book. 2015;35:177-186. doi:10.14694/EdBook_AM.2015.35.177.

Chapman

Hauschild

Robert

. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-2516.

Long

Stroyakovskiy

Gogas

. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial [published online May 29, 2015]. Lancet. pii:S0140-6736(15)60898-4. doi:10.1016/S0140-6736(15)60898-4.

Menzies

Long

. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma. Clin Cancer Res. 2014;20(8):2035-2043. doi:10.1158/1078-0432.CCR-13-2054.

Robert

Karaszewska

Schacter

. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30-39. doi:10.1056/NEJMoa1412690.

Foletto

Haas

. Cutaneous melanoma: new advances in treatment. An Bras Dermatol. 2014;89(2):301-310.

Flaherty

Hodi

Bastian

. Mutation-driven drug development in melanoma. Curr Opin Oncol. 2010;22(3):178-183. doi:10.1097/CCO.0b013e32833888ee.

10.

Carvajal

Antonescu

Wolchok

. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011;305:2327-2334.

11.

Guo

Kong

Flaherty

. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol. 2011;29:2904-2909.

12.

Ribas

Hodi

Callahan

. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med. 2013;368:1365-1366.

13.

Larkin

Chiarion-Sileni

Gonzalez

. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23-34. doi:10.1056/NEJMoa1504030.

14.

Mahoney

Freeman

McDermott

. The next immune-checkpoint inhibitors: PD-1/PD-L blockade in melanoma. Clin Ther. 2015;37(4):764-782. doi:10.1016/j.clinthera.2015.02.018.

15.

Provectus Pharmaceuticals, Inc. PV-10 for melanoma. https://www.pvct.com/pv10melanoma.html. Accessed June 20, 2015.

16.

Thompson

Agarwala

Smithers

. Phase 2 study of intralesional PV-10 in refractory metastatic melanoma. Ann Surg Oncol. 2015;22(7):2135-2142.

17.

Andtbacka

RHI

Kaufman

Collichio

. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma [published online May 26, 2015]. J Clin Oncol. pii:JCO.2014.58.3377. doi:10.1200/JCO.2014.58.3377.

18.

Coventry

Baume

Lilly

. Long-term survival in advanced melanoma patients using repeated therapies: successive immunomodulation improving the odds? Cancer Manag Res. 2015;7:93-103. doi:10.2147/CMAR.S76163.